Quick Facts

• Therapeutic Domain: May assist in managing certain heart rhythm disturbances.
• Primary Use: Prescribed to address supraventricular and ventricular arrhythmias.
• Goal: Used in therapeutic strategies to help regulate the rhythm of the heart.

---

What Аллафорте treats: Main Uses and Benefits

Аллафорте is utilized in therapeutic approaches intended to influence the rhythm of the heart. The medication is an established option for addressing specific types of cardiac arrhythmias.

It is prescribed to individuals to support the maintenance of a regular heart rhythm in the context of supraventricular and ventricular arrhythmias. Its uses align with the goal of managing heart rhythm irregularities, which is a key component of cardiovascular care. The drug may be incorporated into a treatment plan for patients with paroxysmal atrial fibrillation to help manage episodes.

Appropriate use requires a medical professional's assessment to determine if the benefits outweigh potential considerations, consistent with general practices for antiarrhythmic agents.

Regulatory References

1. NIH MedlinePlus guidance on heart arrhythmias

Who can and cannot use Аллафорте?

Eligibility for using Аллафорте is strictly defined by regulatory authorities based on the medicine’s classification as a Class IC Antiarrhythmic.

---

Absolute Contraindications

The medicine is strictly prohibited (contraindicated) for patient populations with underlying structural heart disease, including a history of myocardial infarction or left ventricular dysfunction. Use is also prohibited in patients experiencing severe heart block, severe myocardial insufficiency, or those with a known hypersensitivity to Lappaconitine Hydrobromide or any component of the formulation.

---

Restricted and Conditional Use

Use is generally not established in pediatric patients (children and adolescents) as safety and effectiveness data are currently insufficient for this age group. The medicine is also not recommended for use during pregnancy or lactation due to limited safety information in these populations. Additionally, patients with impaired liver function or impaired kidney function require caution and medical monitoring due to the drug's elimination pathways. The presence of uncorrected electrolyte imbalances also serves as a critical eligibility restriction.

The interaction profile for Аллафорте (Lappaconitine Hydrobromide) outlines the officially documented patterns when co-administered with certain other medicinal products, based strictly on authoritative regulatory labeling. This information is classified into pharmacokinetic and pharmacodynamic domains.

Metabolic and Exposure Interactions

Official documents identify pharmacokinetic interactions involving the CYP3A4 metabolic pathway. Substances that inhibit this enzyme, such as Cimetidine, are documented to increase the plasma concentration and reduce the clearance of Lappaconitine Hydrobromide. Conversely, co-administration with enzyme inducers, such as Phenobarbital, is stated to decrease the plasma concentration and increase the clearance of the active ingredient. These documented interactions modify drug exposure.

Pharmacodynamic Effects

Pharmacodynamic interactions address additive actions on the heart's electrical system. Co-administration with other Antiarrhythmic Agents may result in a documented additive effect on cardiac conduction. The regulatory profile specifically notes a documented risk of increased toxicity when co-administered with Digoxin.

Regulatory Constraints

No specific medicinal products are formally classified as absolute contraindications in the official labeling, and no mandatory timing rules requiring dose separation are documented. The overall classification of these interactions is clinically significant, necessitating attention to potential changes in exposure or additive effects as described in the official documents.

How Аллафорте Works: Pharmacodynamic Mechanism

This medication primarily modulates cardiac electrical activity through the selective, use-dependent blockade of voltage-gated sodium channels ( Nav) located in the myocardial cell membranes. This interaction is concentrated in the channels' open or inactivated states, which occurs more frequently during rapid electrical cycling. The block restricts the fast influx of sodium ions necessary for the initial rapid depolarization (Phase 0) of the cardiac action potential.

The resulting physiological consequence is a reduction in cellular excitability and a significant decrease in the speed at which electrical signals propagate (conduction velocity) across the heart tissue. This decrease in conduction velocity, coupled with a prolonged effective refractory period, alters the tissue-level electrical dynamics. This alteration is crucial for preventing the formation and self-perpetuation of re-entrant electrical circuits, thereby modifying signal pathways within the myocardium.

Additionally, adjunctive components modulate local myocardial tissue metabolism by facilitating anabolic processes and cellular regeneration. This function provides biological support to the myocardial structure, operating in parallel with the primary ion channel modulation.

Аллафорте (Lappaconitine Hydrobromide) is a specialized Anti-Arrhythmia Agent administered exclusively via the oral route in tablet form. Its usage is governed by a strict procedural protocol requiring specialized medical oversight due to its classification as a Class IC medication.

Official Administration Protocol

The dosing schedule is not standardized but must be highly individualized for each patient, determined solely by the prescribing physician following a mandatory titration phase. This process is essential to establish the lowest effective dose for rhythm maintenance. Specific quantitative dose ranges and the exact daily frequency are detailed within the official prescribing information. Treatment is generally structured for long-term maintenance of heart rhythm stability.

Procedural Constraints

Initial therapy and any major adjustments to the dose require the patient to be in a monitored clinical setting suitable for continuous cardiac observation. This necessity underscores the drug's specialized use. Furthermore, the prescribing physician must follow specific established guidelines regarding age-group administration and mandatory dose adjustments for patients presenting with confirmed hepatic or renal impairment. The tablets are to be taken according to the specific timing instructions (with or without food) provided in the official product documentation, ensuring the consistency required for continuous rhythm control. Instructions on the proper handling of a missed dose are also outlined in the guidance for patients.

Аллафорте: Recent Clinical Evidence

---

Evidence for Use in Preventing Atrial Fibrillation Recurrence

Research has explored the active ingredient in small prospective open studies and limited small randomized controlled trials (RCTs) where the active ingredient was studied. These studies examined outcomes related to the maintenance of stable sinus rhythm following acute episodes of Atrial Fibrillation (AF) and Atrial Flutter (AFL). Findings describe measured patterns over follow-up durations extending up to approximately one year, based primarily on small group sizes. The existing evidence is limited and heterogeneous in its structure, contributing to an incomplete picture of rhythm stability.

---

Research on Managing Ventricular Premature Beats

The research examined the active ingredient in randomized, double-blind, cross-over comparison trials. These studies were applied to patients experiencing ventricular premature beats (extrasystoles), primarily those reported as being without pronounced organic heart disease. Trials monitored acute changes in the frequency of these beats, examining a comparison of the prolonged-release formulation (Аллафорте) to the original formulation. Research provides context for short-term changes in these patient groups.

---

Long-Term Studies and Evidence Gaps

The active ingredient was evaluated in studies examining outcomes related to heart rhythm over short-term to intermediate periods of up to 12 months. However, long-term effects are not fully established beyond the one-year mark. Data for certain groups, particularly those with significant underlying cardiac pathology or complex comorbidities, remain insufficient to fully characterize the observed patterns.

---

Evidence Quality and Scientific Uncertainty

The evidence quality varies across studies, often consisting of trials with modest sample sizes and open-label designs. The active ingredient is included in some national guidelines but is not referenced in corresponding guidelines of the European Society of Cardiology (ESC). Comparative evidence is lacking for large-scale, modern randomized trials against international standard agents. This contributes to the overall observation that certainty remains low regarding the drug's relative position in the broader evidence landscape.

Common questions about Аллафорте (FAQ)

---

Q: How does the action of Аллафорте differ from the standard version of Allapinin?

Official information states that the prolonged-release formulation of Аллафорте was designed to mitigate the potential for certain side effects. This formulation aims to minimize the risk of high-concentration-related issues that can occur with the immediate-release version, Allapinin.

---

Q: What specific types of arrhythmias is Аллафорте prescribed for?

According to official regulatory documents, this medicine is prescribed for the management of both supraventricular and ventricular arrhythmias. Its approved purpose is to provide long-term prophylactic antiarrhythmic therapy to help maintain a stable heart rhythm.

---

Q: Why is the long-acting formulation of Аллафорте mentioned to reduce neurological side effects?

The long-acting design aims to prevent high peak concentrations of the drug in the bloodstream. This design aims to minimize high concentrations of the active ingredient, which are associated with an increased risk of concentration-dependent side effects, including those affecting the nervous system (e.g., dizziness or headache).

---

Q: Is it common to feel dizzy or lightheaded when starting to take Аллафорте?

Regulatory documents classify dizziness and headache as Very Common side effects, meaning they may affect more than 1 in 10 people. These effects are reported as frequently observed, particularly when initiating treatment.

---

Q: Is there a known food or drink interaction with Аллафорте, and is it designed to be taken with or without food?

Official product information contains specific timing instructions related to food consumption. Separately, official information explicitly states that the active substance is incompatible with alcohol, and co-administration with alcohol is contraindicated.

---

Q: What happens if I accidentally miss a dose of Аллафорте?

Official product information contains guidance on handling a missed dose. Regulatory documents state that taking a double dose to compensate for a missed dose is strictly prohibited. Specific instructions are provided in the full prescribing information.

---

Q: Are there any special monitoring requirements while taking Аллафорте (e.g., blood tests)?

Regulatory documents specify special monitoring requirements. Before and periodically during treatment, physicians are required to monitor the patient's cardiac function (using an ECG and clinical exam) and assess the water-electrolyte balance in the blood.

---

Q: Why are the pharmacokinetic properties of the long-acting formulation considered important in clinical settings?

The goal of the long-acting formulation is to provide a more stable drug concentration profile over time. This design is intended to support rhythm maintenance while reducing the concentration-dependent side effects associated with high drug peaks.

---

Q: Are there any known issues with taking Аллафорте and driving or operating machinery?

Official documents include a caution regarding performing activities that require heightened attention and fast psychomotor reactions, such as driving or operating machinery. This is noted due to the possibility of adverse effects like dizziness or impaired coordination.

---

Q: What is the official guidance on managing a temporary worsening of arrhythmia when starting a drug like Аллафорте?

Regulatory documents specify that initial therapy and any major dose changes require the patient to be in a strictly monitored clinical setting. This is necessary because of the risk of proarrhythmia, which is the potential for the antiarrhythmic drug to worsen or create new heart rhythm problems.

---

Q: Why do official documents emphasize that the drug is only for serious heart rhythm problems?

This emphasis reflects the drug’s classification as a specialized antiarrhythmic agent (Class IC). Official product information highlights the need for specialized medical oversight due to the drug's narrow therapeutic range and the documented risk of severe adverse cardiac events.

---

Q: Can Аллафорте be taken along with beta-blockers or calcium channel blockers?

Regulatory warnings mention that combining the drug with other antiarrhythmic agents requires caution. This is due to an increased risk of additive electrical effects on the heart.

---

Q: Is it necessary to avoid alcohol while taking Аллафорте?

Official product information explicitly classifies the active substance as incompatible with alcohol (ethanol). This incompatibility is noted because alcohol consumption may influence drug metabolism and potentially increase the risk of complications during therapy.

---

Q: How quickly can a patient generally expect to see the effect of Аллафорте?

Regulatory pharmacokinetic data provides insight into the drug's absorption rate. This data indicates that the maximum concentration of the active substance after oral administration is typically reached in approximately four to five hours.

---

Q: Are there differences in the drug's effect between the 25 mg and 50 mg tablets?

Official regulatory documents describe the 50 mg dose as a possible adjustment used when the therapeutic effect of a lower dose is deemed insufficient by the prescribing clinician. This adjustment indicates that the higher dose is used to achieve a necessary clinical effect.

---

Q: Does Аллафорте affect blood pressure?

Yes. Official regulatory documents list increased blood pressure as a common side effect of the medicine.

---

Q: What does the term 'prolongation of the half-life' mean for a patient taking this medicine?

The half-life refers to how long the drug remains active in the body. Regulatory documents note that the half-life is significantly prolonged (meaning the drug stays in the body longer) in patients with confirmed kidney or liver failure.

---

Q: Is it normal to experience blurred vision as a side effect?

Official regulatory documents classify double vision (diplopia) as a Very Common side effect (affecting more than 1 in 10 people). Double vision is a documented type of visual disturbance associated with the active ingredient.

---

Q: Does the drug have any known interaction with common anticoagulants (blood thinners)?

Official documents state that there is currently no data on the adverse effect of the active ingredient on the effectiveness or safety of indirect anticoagulants (a class of blood thinners).

The official regulatory requirements for storing Аллафорте (allapinin) tablets focus on maintaining product stability and ensuring safety. The medicine must be stored in a dry place and protected from light at a temperature not exceeding 25 C.

Official Storage and Disposal Profile

Requirement	Classification
Storage Temperature	Not exceeding 25 C
Environmental Protection	Protected from light and moisture
Official Shelf-Life	Three years (under stated conditions)

All official labeling mandates that the product be kept out of the reach of children. The shelf-life of the tablets is three years when stored under the defined environmental conditions. Disposal of any unused or expired product must be executed strictly according to local pharmaceutical waste management procedures and specific regulatory requirements.